We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lifts Clinical Hold on Aprea’s Eprenetapopt nonHodgkin’s Lymphoma Program
FDA Lifts Clinical Hold on Aprea’s Eprenetapopt nonHodgkin’s Lymphoma Program
Aprea Therapeutics has received FDA clearance to continue its eprenetapopt development, with the lifting of a full clinical hold placed last summer on the drug’s nonHodgkin’s lymphoma clinical trial program.